Bcl-2 on the brink of breakthroughs in cancer treatment

Cell Death and Differentiation

Volumn 25, Issue 1, 2018, Pages 3-6

  Reed, John C ^a,b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; VENETOCLAX; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER RESISTANCE; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 85045195827     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2017.188     Document Type: Review

References (17)

1. Ruefli-Brasse A, et al. Biochem J 2017; 474: 3643-3657.
2. Ashkenazi A, et al. Nat Rev Drug Discov 2017; 16: 273-284.
3. Pekarsky Y, et al. Cell Death Differ 2018; 25: 21-26.
4. Adams JM, et al. Cell Death Differ 2018; 25: 27-36.
5. Kale J, et al. Cell Death Differ 2018; 25: 65-80.
6. Kalkavan H, et al. Cell Death Differ 2018; 25: 46-55.
7. Strasser A, et al. Cell Death Differ 2018; 25: 13-20.
8. Montero J, et al. Cell Death Differ 2018; 25: 56-64.
9. Opferman JT, et al. Cell Death Differ 2018; 25: 37-45.
10. Hanada M, et al. Blood 1993; 82: 1820-1828.
11. Miyashita T, et al. Cancer Res 1992; 52: 5407-5411.
12. Reed JC. Science 2011; 334: 1075-1076.
13. Souers AJ, et al. Nat Med 2013; 19: 202-208.
14. Erlanson DA, et al. Nat Rev Drug Discov 2016; 15: 605-619.
15. Byrd JC, et al. Blood 2002; 99: 1038-1043.
16. Tischner D Cell Death Discov 2010; 1: E48.
17. Jung-Ha H, et al. Hum Pathol 1998; 29: 723-728.